ClinicalTrials.gg
CompletedNCT05351892Updated Jul 19, 2022

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

A Phase 1 interventional study of Elinzanetant (BAY3427080) in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes and Healthy Volunteers, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
11th of 13
18 · median 64
Started
2022
with 4 others
Phase 1
7 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 11th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 1, and was the 8th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.

The study treatment, elinzanetant, is under development to treat symptoms caused by hormonal changes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.

Participants of this study will be healthy and will have no benefit from administration of elinzanetant. This study, however, will provide information on how to use elinzanetant in people with vasomotor symptoms.

In previous studies, capsules containing smaller amounts of elinzanetant have been used. To reach the daily dose intended for treatment, 3 of these capsules had to be taken once a day. To reduce the pill burden and make it easier for patients to stick to the treatment, capsules with a higher amount of elinzanetant have been developed.

The main purpose of this study is to learn how much of the study treatment elinzanetant gets into the participants' blood when the same dose is taken as new capsule formulation compared to the old capsule formulation.

To answer this question, the researchers will compare:

  • The (average) total level of elinzanetant in the blood (also called AUC)
  • The (average) highest level of elinzanetant in the blood (also called Cmax) between both capsule formulations after taking one dose of each.

In addition, the researchers want to compare how much of the new and old elinzanetant formulations get into the blood after intake for 9 subsequent days.

All participants will take both formulations by mouth during the study. Each participant will be in the study for up to 12 weeks, including 10 treatment days for each formulation. Participants will stay in-house for 14 days per capsule formulation. In addition, one screening visit to the study site is planned.

During the study, the study doctor and their team will:

  • Do physical examinations
  • Take blood and urine samples
  • Check vital signs
  • Examine the participants' heart health using electrocardiogram (ECG)
  • Ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

03

Conditions studied

  • Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
  • Hot Flashes
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 45 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation of the investigator, including medical history, physical examination, blood pressure, pulse rate, body temperature, laboratory tests, and cardiac monitoring
  • Body weight of at least 50 kg and (BMI) within the range 18 to 30 kg/m\^2 (inclusive)
  • Male or female
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention(s) will not be normal
  • Known or suspected allergy or to elinzanetant or any of their
  • Any history of or ongoing endocrine disease
  • Any known impairment of testosterone synthesis and metabolism
  • Poor venous access
  • History of alcohol or drug abuse
  • Regular use of prescription drugs, over-the-counter drugs, supplements (e.g. carnitine products, anabolics, high dose vitamins) or herbal products within 2 weeks or 5 half-lives (whichever longer) prior to the first study intervention administration
  • Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them within 4 weeks prior to the first study intervention administration, e.g. any drug, any inducers including St John's Wort, any proton pump inhibitors, or any other drug known to induce liver enzymes (e.g. dexamethasone, barbiturates), and 2 weeks for any drug known to inhibit liver enzymes (e.g. itraconazole, macrolides) as well as grapefruit.
  • findings in the (ECG), such as second or third degree AV block, prolongation of ECG parameters ( > 450 msec, QRS > 120 msec)
  • Clinically relevant deviations of the screened laboratory parameters from reference ranges at screening or Day -1.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment A-B

    Participants will receive a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.

    Drug: Elinzanetant (BAY3427080)

  • Experimental
    Treatment B-A

    Participants will receive a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.

    Drug: Elinzanetant (BAY3427080)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve from zero to infinity of elinzanetant after single dose administration (AUC)

    AUC from time 0 to the last data point greater than lower limit of quantification (LLOQ) (AUC\[0-tlast\]) will be used as a primary parameter, if AUC cannot be determined in all participants.

    Time frame: 0 to 84 hours after first dose on Study Day 1

  2. Maximum observed drug concentration of elinzanetant in plasma after single dose administration (Cmax)

    Time frame: 0 to 84 hours after first dose on Study Day 1

Secondary outcomes

  1. Area under the concentration versus time curve from administration of last dose until 24 hours after last dose of multiple dosing (AUC[0-24]md)

    Time frame: 0 to 24 hours post-dose on Study Day 12/13

  2. Maximum observed drug concentration of elinzanetant in plasma after multiple dose administration (Cmax,md)

    Time frame: 0 to 24 hours post-dose on Study Day 12/13

  3. Observed drug concentration of elinzanetant in plasma prior to next dose administration (Ctrough)

    Time frame: 0 to 24 hours post-dose on Study Day 12/13

  4. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: After first administration of study intervention until follow up (Day 14 of Period 2)

07

Study locations

1 site
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2022, 1 month.

Of 10 phase 1 interventional studies under Hot Flashes, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 9. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2022
First posted
Apr 28, 2022
StartActual
May 4, 2022
Primary completionActual
Jun 9, 2022
CompletionActual
Jun 20, 2022
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05351892
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 28, 2022
Start date
May 4, 2022
Primary completion
Jun 9, 2022
Completion
Jun 20, 2022
Last update
Jul 19, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion